Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) announced its participation in the Jefferies Global Healthcare Conference on June 9, 2022, at 4:00 p.m. E.T. This clinical-stage company focuses on innovative treatments for serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), which currently lacks approved therapies. Their lead candidate, efruxifermin (EFX), is designed for convenient weekly subcutaneous dosing and is under evaluation in two Phase 2b clinical trials. The presentation will be webcasted live, with archived replays available on their website.

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022, at 4:00 p.m. E.T.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2/F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Akero is headquartered in South San Francisco. Visit us at www.akerotx.com for more information.

Investor Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com

Media Contact:
650.487.6488
media@akerotx.com

FAQ

When will Akero Therapeutics present at the Jefferies Global Healthcare Conference?

Akero Therapeutics will present on June 9, 2022, at 4:00 p.m. E.T.

Where can I watch the Akero Therapeutics conference presentation?

The presentation will be available via a live webcast on the investor relations section of Akero's website.

What is Akero Therapeutics' lead product candidate?

The lead product candidate is efruxifermin (EFX), developed for treating non-alcoholic steatohepatitis (NASH).

What are the ongoing clinical trials for efruxifermin?

Efruxifermin is currently being evaluated in two Phase 2b trials: the HARMONY study for pre-cirrhotic NASH and the SYMMETRY study for cirrhotic NASH.

What is the significance of efruxifermin in treating NASH?

Efruxifermin aims to provide a potential best-in-class treatment for NASH, a disease with no currently approved therapies.